Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Piper Jaffray has a $6.00 Price Target
Let’s GOOOOOOO TIT
Before you assume, learn the facts. Before you judge, understand why. Before you hurt someone, feel. Before you speak, think.
Or if you don’t like anonymous assume quotes perhaps you may like what Daniel tiger says from Daniel Tiger Neighborhood
If you feels so mad and your about to roar
Take a deep breath
And count to four
.....
I feel so glad and about to roar TITAN
rOAR TITAN
ROCKO??
What are the odds ROCKO McNally announces something special on the 29th??
We need 35 million for upto q1 2020 how great would it be if we could get appreciation to get the warrants in play
ROCKO! ROCKO! ROCKO!
Titan Financial, I’m liking the sounds of that creative financing. a win win for everyone involved
I can’t wait until this gets some major announcements....
Computer assisted technology software partner if like a lot of any previous partners we are most likely partnering with best in class software providers ...
Who offers best in class software surgical solutions???
Would a verb show up?
Hypothetically they announced the software partner and it is verb surgical or Ethicon Digital...
Would this raise the share price??
I would think a little bit but watching this wouldn’t be surprised either way... thoughts????
FDA STUDIES BEGIN JUNE for the 510k Clearance
Choo! Choo! Chug a lugga, Chug a lugga, SCOoooop! SCOOOOP!
ANIMAL Models & HUMAN CADAVERS which go on the record and our recorded as “studies under good regulatory practices”
Following that they plan on filing an I D E
Investigational Device Exemption for the FDA to allow a limited study in Human Subjects by years end
That all leads up to the regulatory filing clearance by 2019 year end
Let’s hope lil birdy saying something special is gonna be announced on our special meeting 5/29! glg20 you know a thing or two about lil birdies over the years
What are the chances Something Special is Announced in our AGM?
What could it be if it is special??
What could it do for share price??
I’ll take a stab, software partner announced & end effector partner announced
Verb Software/JNJ end effector
5 day rally gets us to 20 + a share
Anyone wanna play the hypothetical???
This stock just baffles me, I wouldn’t be surprised if and when a huge Fortune 500 Company joint venture partner or distribution / software partner is announced we continue to see little or no appreciation in the stock price...
I got my fingers crossed ?? this doesn’t happen ...... les goooo little sport engine that could!!!!
It will be like Christmas Day when the Announcement is made .....
Letsssss Gooooooo TIT
FLY! BABY! FLY! We missed yah bud!!! Interesting connections here with Titan, doesn’t seem like the little engine that could anymore sort of feels like a baby intuitive in the making.... Now it’s time for the market to catch on and give this share price some wings
Former MAKO CEO JOINS TITAN MEDICAL - TICKER TMDI
https://apple.news/AgYXFxFsEROmMHtrBEJGGFQ
MAKO GOT BOUGHT BY STRYKER MAYBE TMDI NEXT
Found this VERY Interesting ARTICLE about the SHORTS and MAKO - LEEEES GO TIT
NEW YORK ( TheStreet) -- Medical equipment manufacturer Stryker ( SYK - Get Report) said it will buy MAKO Surgical ( MAKO for $30 a share, in a deal that could smoke out short sellers of the robotic orthopedic equipment maker.
Stryker's acquisition values MAKO Surgical shares at $1.65 billion in cash, or about an 85% premium to the company's closing share price on Tuesday. The acquisition may prove to be a big boost to the credibility of makers of controversial robotic medical equipment. It also may prove painful for short-sellers who have piled into short positions in the shares of MAKO and Intuitive Surgical, given lingering questions about the safety of medical robots.
MAKO is among the most shorted stocks on the Nasdaq with 10,313,353 of its 47 million shares sold short as of September 13. That represents a short interest of about 22% of MAKO's outstanding shares. MAKO surgical shares were up over 82% to $29.39 in Wednesday afternoon trading.
For short-term MAKO shareholders, Wednesday's acquisition by Stryker comes at a significant short-term premium, however it is roughly 33% below the company's all-time share price high and comes at a time when the company has shored up its cash balances through secondary stock offerings and shown a better ability to meet its earnings guidance.
https://www.google.com/amp/s/www.thestreet.com/amp/story/12048229/1/strykers-30-a-share-mako-surgical-deal-smokes-out-shorts.html
Over 300k shares traded in 15 minutes a high of 3.14, LES GOOO
Have A FEELING JOINT VENTURE ANOUNCEMent on the 29th Of May........
Who could are partnership be with SURGERY 4.0 on our website and I have heard others tweet about SURGERY 4.0 in the past....
What would be a huge curveball would be if it’s Intuitive either way who ever the partners unfold to be we are headed FINALLY in the right direction
Lesssssss GO TIT
The AGM is up on sedar, Thier Calling it a SPECIAL MEETING
My mom thinks I’m special, and I like special meetings!!!!!
Leeeeeeeeeeeeeees GO
Date: April 24, 2019
AMENDED
To: All Canadian Securities Regulatory Authorities
Subject: TITAN MEDICAL INC.
100 University Avenue, 8th floor Toronto ON, M5J 2Y1 www.computershare.com
Dear Sir/Madam:
We advise of the following with respect to the upcoming Meeting of Security Holders for the subject
Meeting Type : Annual General and Special Meeting
Meeting Date : May 29, 2019
Meeting Location (if available) :
Issuer sending proxy related materials directly to NOBO: Issuer paying for delivery to OBO:
Notice and Access (NAA)
NAA for Beneficial Holders NAA for Registered Holders
Voting Security Details: Description
COMMON SHARES
Sincerely,
Computershare
Agent for TITAN Medical Inc
CUSIP Number ISIN
88830X819 CA88830X8199
We have over 100 engineers around the globe working on SPORT...
Watched the AGM from 2015 with the good ole boys John H and David F running the show....
Where we were in 2014 and design was very interesting.....
data capture,computer assisted technology, autonomous features to help the surgeons pre-surgery so the computer assisted tech moves the instruments in concert to the right places in the patient ....
I think I got invested in March of 2014, currently down over 40k but super optimistic about the future due to the intellectual property that keeps coming and coming and coming.
An IP Attorney will tell you the true net worth of any business in this world is their intellectual Property/patents and ability to protect
SPORT finally coming to the finish line, this thing will explode once our partners are announced....
“the Company intends to utilize a direct sales force and/or distribution partner(s) to initiate marketing of the SPORT Surgical System to hospitals.” MD&A from SEDAR
Partner / partner sssss??
Hmmmm
I wonder if this could be JNJ and Medtronic??
Maybe we are gonna license with multiple medical distribution partners
Can’t Afford Surgery? In China, Millions Chip In Half a Penny to Cover You
Fintech companies are looking to fill gaps in China’s health insurance sector, getting people to sign up for crowdfunded medical coverage
When a 5-year-old girl in Shanghai suffered brain damage late last year after falling off a bunk bed, millions of strangers all over China helped foot her surgical bills.
The child’s family didn’t pay anything upfront for the coverage, and received a 300,000 yuan (about $44,730) payout that required each contributor to fork out just 0.03 yuan (about half a cent).
Internet financial-technology startups in China have disrupted its banking, payments and lending industries, and they are now trying to fill gaps in the country’s health insurance sector.
Last October, billionaire Jack Ma’s Ant Financial Services Group rolled out a “mutual-protection” plan for users of Alipay, its wildly popular payments network, and has so far signed up 50 million participants.
The plan provides lump-sum payouts for 100 critical injuries or diseases, including cancerous tumors and some types of paralysis. Ant said this month it is aiming for 300 million participants in the next two years.
Ant is one of about a dozen private startups in China trying to get more people to sign up for crowdfunded medical coverage for themselves or on behalf of their children and elderly parents. Even Chinese ride-hailing giant Didi Chuxing Technology Co. launched a similar product a few months ago.
The child in Shanghai who underwent brain surgery last November was the first beneficiary of Ant’s Xiang Hu Bao program. The company declined to provide contact details for her family.
Another 18 individuals, as of earlier this month, have since received payouts from Ant’s mutual-aid product, and the contribution of each member has dropped to about 0.01 yuan per claim, paid using Alipay. Ant says it collects an 8% “administrative charge” from each payout.
The fintech companies stress their crowdsourced aid programs aren’t insurance, to avoid running afoul of regulations. Ant initially paired with a licensed Chinese insurer when it first launched its mutual-protection plan, but ended the partnership after Chinese regulators accused the insurer of misleading marketing and disclosure lapses.
The general idea is that small amounts of money can be pooled into large sums. China’s giant population means the cost of coverage can theoretically be spread across hundreds of millions of people at negligible cost to each individual.
When participants file for claims, the companies say they have to verify the information provided before making payouts. That can include interviewing the individuals, reviewing their medical records and contacting the hospitals they have sought treatment from.
Liu Xucheng, a 26-year-old e-commerce professional in Hangzhou, said he signed up for Ant’s mutual-aid product last year. In March, when his newborn daughter was 30 days old, he signed her up for coverage as well.
Mr. Liu and his family members also participate in a similar mutual-protection plan called Shuidi Huzhu. So far, Mr. Liu said, his family has contributed about 50 yuan a year toward other people’s claims on the two platforms.
“Because the cost is low, it’s acceptable,” Mr. Liu said, describing the coverage as basic protection.
More than 90% of China’s population has some form of public health insurance that covers basic drugs and the bulk of hospitalization costs after a deductible is paid. Patients often incur high out-of-pocket costs for imported drugs and costlier medical treatments, and many people can’t afford commercial health insurance.
Health-Care System (Jan. 4, 2015)
“In some sense, it’s a substitute for insurance,” said He Xiaowei, associate professor of insurance and economics at the University of International Business and Economics in Beijing, referring to the mutual-protection plans offered by startups.
He Junlin, a 28-year-old financial professional in the southwest city of Chengdu, joined Ant’s mutual-protection platform last November. So far, he said, he has paid less than 0.1 yuan in total toward other people’s claims during the five months of his membership.
“I’m young. The chance of getting sick is low, so I think having Xiang Hu Bao alone is sufficient,” he said, explaining why he hasn’t purchased commercial health coverage for himself.
Besides the risk of a regulatory clampdown on the burgeoning industry, there is also no guarantee the fintech startups will be around to pay out claims in the long term, especially if they run into financial difficulties themselves.
If the technology startups fail, people will be left without the coverage they thought they had, said Chen Dongmei, an associate professor of insurance at Fudan University in Shanghai. “That’s a huge risk for the consumers,” she added.
Shen Peng, founder and chief executive officer at Shuidi Huzhu—whose name translates into Waterdrop Mutual Help—said the idea behind its platform is that people can “use a small amount of money to cope with big illnesses.”
The three-year-old startup’s backers include Chinese internet giants Tencent Holdings Ltd. and Meituan Dianping, and it has more than 78 million members.
Shuidi Huzhu offers different types of mutual-coverage plans, including one that makes payouts for people diagnosed with cancer. The company isn’t profitable yet, according to Mr. Shen, who said the company’s primary goal is to help serve “social interests.”
Mr. Shen said many of its plans’ participants live in smaller cities and don’t have commercial insurance. So far, the platform has paid out more than 400 million yuan in total to more than 3,000 people with critical diseases.
In one case described on its website, Yan Guohua, a 62-year-old farmer in Huai’an, a small city in eastern China, was diagnosed with lung cancer in January. A member of Shuidi Huzhu’s plan for older people, he received a payment of 30,061 yuan this March. During his 380 days of membership, Mr. Yan paid a total of 15.7 yuan. He couldn’t be reached for comment.
Zhou Wei in Shanghai
Happy Easter Sport19, let’s hope Titan pulls out the bunny from the rebranding hat and their efforts get us longs in the bull run we were destined for and more
We’re a 75.38 M mkt cap per TD Ameritrade
During 2018, the Company confirmed with the Food and Drug Administration of the United States Department of Health and Human Services (the “FDA”), that confirmatory human data will be required for its planned regulatory submission.
The performance of human surgeries with the SPORT Surgical System will require an Investigational Device Exemption (“IDE”) from the FDA, which must be submitted and approved in advance.
Further, the recruitment of surgeons from multiple hospital sites will be necessary to perform the surgeries. Each of these sites will require approval of their independent Institutional Review Board (“IRB”) to approve the studies. During the first three quarters of 2019, the Company plans to pursue the recruitment of surgeons and hospitals for the studies, IDE approval by the FDA, and approvals by the IRB of each hospital, in preparation for the confirmatory human studies planned for completion during the fourth quarter.
A complete estimate of the timing and costs for development milestones beyond 2019 is speculative. The Company estimates that a minimum of US $64.1 million will be required to fund its operations in 2019. Based on the cash and cash equivalents on hand, including deposits with suppliers as at December 31, 2018, the Company believes that it will need to raise approximately $45 million to fund it operations in 2019.
This includes projected capital resources necessary for the Company to submit its 510(k) application to the FDA and apply for CE Marking which indicates that a product for sale within the European Economic Area (EEA) has been assessed to conform with health safety and environmental protection requirements. If successful with those efforts, the Company expects to proceed with early commercialization activities in the U.S. in 2020.
Given the uncertainty of, among other things, product development timelines, regulatory processes and requirements (such as live animal and human cadaver studies and confirmatory human studies), as well as the availability of required capital to fund development and operating
12
costs, actual costs and development times may exceed management’s current expectations and an accurate estimate of the future costs of the regulatory phases and development milestones beyond 2019 is not possible at this time.
The Company’s current plan is to raise sufficient financing and continue the development and commence commercialization of the SPORT Surgical System at estimated incremental costs, and according to the timeline, as set forth in the table below.
Current Development Plan
The Company anticipates development costs through to the fourth quarter of 2019 to be as set out in the table below (the “Current Development Plan”).
Milestone 4
Document results of confidence build unit testing, implement subsystem design improvements and schedule preliminary audit of quality system by European Notified Body
Q1 2019
Milestone 5
Update system design and related hardware and software
documentation
Verify production system operation with clinical experts under rigorous formal (summative) human factors evaluation under simulated robotic manipulation exercises
Initiate SPORT Surgical System Design Freeze
Initiate preclinical live animal (swine) and cadaver studies according to final protocols for FDA submittal
Submit Investigational Device
Exemption (IDE) application to FDA
Q2 2019
Submit draft protocols to FDA in Q- submission(s) for comment
Milestone 6
Milestone 7
Complete and document preclinical live animal (swine) and cadaver studies according to final protocols for FDA submittal
Obtain ISO 13485 Certification Receive IDE approval from FDA
Complete and document human confirmatory studies under IDE protocols for FDA submittal
Submit Technical File to European Notified Body for review for CE Mark
Submit 510(k) application to FDA
Q3 2019 –
Q4 2019
Soooooooo sloooooow And loooow
Lowered my cost average to 7.14, LETS GO Titan the mighty little Canadian robotic engine team that could!!! CHOO CHOO Design Freeze , here we come!!!!
During 2018, the Company confirmed with the Food and Drug Administration of the United States Department of Health and Human Services (the “FDA”), that confirmatory human data will be required for its planned regulatory submission.
The performance of human surgeries with the SPORT Surgical System will require an Investigational Device Exemption (“IDE”) from the FDA, which must be submitted and approved in advance.
Further, the recruitment of surgeons from multiple hospital sites will be necessary to perform the surgeries. Each of these sites will require approval of their independent Institutional Review Board (“IRB”) to approve the studies.
During the first three quarters of 2019, the Company plans to pursue the recruitment of surgeons and hospitals for the studies, IDE approval by the FDA, and approvals by the IRB of each hospital, in preparation for the confirmatory human studies planned for completion during the fourth quarter.
A complete estimate of the timing and costs for development milestones beyond 2019 is speculative.
The Company estimates that a minimum of US $64.1 million will be required to fund its operations in 2019. Based on the cash and cash equivalents on hand, including deposits with suppliers as at December 31, 2018, the Company believes that it will need to raise approximately $45 million to fund it operations in 2019.
This includes projected capital resources necessary for the Company to submit its 510(k) application to the FDA and apply for CE Marking which indicates that a product for sale within the European Economic Area (EEA) has been assessed to conform with health safety and environmental protection requirements.
If successful with those efforts, the Company expects to proceed with early commercialization activities in the U.S. in 2020.
Milestone 4 Q1 2019 16 million
Document results of confidence build unit testing, implement subsystem design improvements and schedule preliminary audit of quality system by European Notified Body
Milestone 5
16.9(2) Q2 2019
Update system design and related hardware and software documentation
Verify production system operation with clinical experts under rigorous formal (summative) human factors evaluation under simulated robotic manipulation exercises
Initiate SPORT Surgical System Design Freeze
Initiate preclinical live animal (swine) and cadaver studies according to final protocols for FDA submittal
Submit Investigational Device Exemption (IDE) application to FDA
Submit draft protocols to FDA in Q- submission(s) for comment
Completed
Milestone 7 Q2/Q3 2019
Complete and document preclinical live animal (swine) and cadaver studies according to final protocols for FDA submittal
Obtain ISO 13485 Certification
Receive IDE approval from FDA
Complete and document human confirmatory studies under IDE protocols for FDA submittal
Submit Technical File to European
Notified Body for review for CE Mark
Submit 510(k) application to FDA
I lowered my cost basis from 12 to 8.24 today! Pissed my entire order didn’t fill at 2.35
Hoping to get to around 6 pps gotta a lil powder in the keg left...
Who thinks she’s going lower? Higher?? And what trend will start to emerge from Monday on, don’t wanna be on the sidelines while this takes off
Happy to have you back IITF, any thoughts on Dennis Fowler and his new Opportunity??
April 15th around the corner, maybe some balseeee investors are cashing out and getting back in 30 delays and claiming then losses??
anyone on the board know how an investor claims those as losses then can buy back in thirty days??
Seems sketchy and not legal for some reason
Thank you Rocko For all you do man!!
Where does Karl Storz fit in your opinion.... we see dots with IRCAD & KS, Are Boy Fowler CMO new job opportunity, highly involved in this arena...could they be a player in the fold?
Could rebranding be a reference to our “PARTNERS”
Thank the lord for some positivity, it seems the only posters here are the selfpity doldrums.(most likely by design)
If Karl Storz is our instrument supplier how does this shake out?
BigT you think we still are a buyout candidate if this was the case? IF KS is the supplier could we go it alone with a KS partnership ?
Who left?
The last raise just gave me thirty million reasons to keep investing, looking forward to this game changing technology entering the market and disrupting the broken hospital economy.
A great read in the recent Bloomberg magazine affirms TITAN is headed in the right direction
SCOOP THEIR IT IS!!!!!
https://www.bloomberg.com/news/features/2019-03-26/the-world-s-cheapest-hospital-has-to-get-even-cheaper
Global Temperatures are Heating Up, lil birdy told me the snicker factor here is about to BURN UP the ATMOSPHERE at ROckelle Corp, the devil is inthe details, LETS GO RKLC
This is a Grey Wolf about to ATTACK the PENNYLanderella’s
My pps is 12, no powder in the keg/ still makes me quiver when I see -40k in my broker account
Yikes, this too shall pass
Best of the best, BIG MOOOVES AHEAD
Whose Titan Media???......ABOUT TITAN MEDICAL
Titan Media casts itself as a research and development stage company.
Advice Robot Master Follow the patents.... Not to mention one of the engineers that worked on Sport with Dennis Fowler in Columbia worked with VERB but Today is with Auris, and Fowler with Karl Storz
Titan/JNJ/KS/Auris
HUGE AH PLAY HERE MAGA HUGE AH FULL STeAM AHEAD CHOO CHOo
KAKAKAAAAA BOOooOOM Time
Said ah BOOOOOOm Sha ka la ka
BOOOOOOOOOOOOOOOOOOOOM